FAP-targeted PET and near-infrared fluorescence imaging for resectable non-small cell lung cancer
Official title: Visualization Study on Tumor Progression Mechanisms and Key Molecular Functions in Neoadjuvant Immunotherapy for Lung Cancer: Preoperative Efficacy Prediction and Intraoperative Fluorescence Navigation
Run by Peking University People's Hospital · NCT07498933 · Data updated 2026-11-12
We are testing whether FAP-targeted PET and near-infrared fluorescence can help find residual tumor and guide surgery in people with stage II–IIIB resectable non-small cell lung cancer after neoadjuvant therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | June 3, 2025 |
| Main results expected | October 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT07498933 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 with biopsy-proven, resectable stage II–IIIB non-small cell lung cancer who have complete clinical and imaging data and have completed at least three cycles of neoadjuvant therapy are the ideal candidates.
✕Probably not a fit
Patients who have other concurrent malignancies, received prior anti-tumor treatments outside the protocol, have insufficient tumor tissue, poor-quality PET imaging, or who had fewer than three cycles of neoadjuvant therapy are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, prospective diagnostic study in patients with stage II–IIIB resectable non-small cell lung cancer who have completed neoadjuvant therapy. Participants undergo preoperative FAP-targeted PET/CT and then fluorescence imaging with an EB-FAPI probe one week before surgery; intraoperative near-infrared fluorescence is used to help localize lesions. After resection, ex vivo fluorescence mapping and systematic multipoint sampling (tumor center, margin, adjacent normal tissue) are performed alongside routine pathological sampling and immunohistochemistry. The study compares the localization accuracy and concordance of PET and fluorescence signals with pathological gold standards and tests whether fluorescence-guided sampling reduces false-negative pathology and improves detection of residual tumor.
Why it matters
Potential benefit: If successful, this approach could make it easier for surgeons and pathologists to find residual tumor after neoadjuvant therapy, improving surgical guidance and pathological detection.
How similar studies have gone: FAP-targeted PET imaging has shown promising tumor detection in prior studies, but combining FAP-targeted PET with near-infrared fluorescence for intraoperative tumor bed delineation is novel and largely exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 70 years old; * Have complete clinical and imaging data; * Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer; * Able to retain sufficient tumor tissue for testing and research; * Sign informed consent. Exclusion Criteria: * Previously combined with other malignant tumors or received other anti-tumor treatments; * Failure to collect sufficient tumor tissue for testing and research; * The duration of neoadjuvant therapy is less than 3 cycles; * The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing; * Lack of clinical and imaging data; * There are situations where other researchers consider it inappropriate to participate in this study
Where it's running
-
Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Hao Li, MD — Peking University People's Hospital
- Study coordinator: Kezhong Chen, MD
- Email: mdkzchen@163.com
- Phone: +86-010-88325983
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PET scan targeting CDH3 for lung tumors
This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.
-
Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific
This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.
-
Neoadjuvant Cemiplimab + Dupilumab in Early-Stage NSCLC
This study tests whether giving cemiplimab with dupilumab before surgery can be safe and help shrink tumors in people with early-stage non-small cell lung cancer.
-
Targeting Integrin αvβ6 for PET Imaging in Cancer
This study is testing a new imaging tool to see if it can help doctors better diagnose and stage certain cancers, like lung and breast cancer, by using a special scan that targets a specific protein found in tumors.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.